Navigation Links
Awareness of Genzyme's Renvela(R) (Sevelamer Carbonate) is High, Although Uptake of this New Phosphate Binding Agent has Been Slower than Nephrologists and Renal Dietitians Initially Expected
Date:5/23/2008

EXTON, Pa., May 23 /PRNewswire/ -- BioTrends Research Group, Inc. released Wave 1 of its LaunchTrends(TM): Renvela report, the second in a multi-phase syndicated market research project tracking the launch of Renvela from baseline awareness through the first six months of product availability. The baseline report was published in December 2007. Wave 1 was fielded in April 2008, one month post Renvela launch, and provides quantitative information from 30 clinical Nephrologists and 30 Renal Dietitians (RDs) in the US, and qualitative information from a subset of 15 respondents in each group.

While virtually all Nephrologists and RDs are aware of Renvela, the next generation Renagel (sevelamer hydrochloride), the vast majority have not yet tried the new phosphate binder. Reimbursement is currently the biggest obstacle to use. Genzyme representatives seem to have increased their contact frequency compared to competitors in their promotion of this new product -- most often focusing on Renvela's similarity to Renagel but with fewer incidences of acidosis and better GI tolerability, according to Nephrologists and RDs. Renvela trials for the most part have been in patients switched from Renagel or naive to binder therapy, although depending on patient types, there are switches from competitive products. Each binder is associated with a variety of attributes and each is associated with unique concerns. Renvela is currently perceived to be the best choice for patients with metabolic acidosis.

Despite slower uptake than MDs and RDs predicted in the baseline research, Renvela share is expected to increase in the next six months among both dialysis and CKD patients.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (http://www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact Jennifer Robinson at (610) 363-3872 or jrobinson@bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MultiVu Video Feed: Allergan, Inc. Partners With "Project Runway" Designer Kara Saun and Gen Art Fresh Faces In Fashion to Raise Awareness About Excessive Underarm Sweating
2. CDC Awards NATT Funding to Improve Blood Clot Awareness
3. The Food Allergy & Anaphylaxis Network (FAAN) and Verus Pharmaceuticals Work Together to Raise Awareness of Food Allergies
4. Answers.coms WikiAnswers Supervisors Rallying for National Breast Cancer Awareness Month
5. SleepQuest Raises Awareness of Sleep Disorders
6. Cardiac Science Unveils Major Brand Change; Strategy to Lift Brand Awareness
7. Actress and Mom Lori Loughlin Raises Awareness About the Potential Dangers of Drowsy Driving During Allergy Season
8. Shire Launches Nationwide Adult ADHD Mobile Awareness Tour
9. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
10. Study Finds Widespread Vitamin and Mineral Use Among Cancer Survivors, Although Benefits of Such Use Remain Unclear
11. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) ... precise treatments and faster cures for prostate cancer. Members of the Class of ... 15 countries. Read More About the Class of 2016 ... ... ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, ... after being treated for breast cancer benefitted from an injection of stem cells derived ... debilitating, frequent side effect of cancer treatment. , Lymphedema refers to the ...
Breaking Biology Technology:
(Date:6/15/2016)... 2016 Transparency Market Research ... Market by Application Market - Global Industry Analysis Size Share ... the report, the  global gesture recognition market  was ... is estimated to grow at a CAGR of ... Increasing application of gesture recognition technology ...
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
(Date:6/1/2016)... -- Favorable Government Initiatives Coupled With Implementation ... to Boost Global Biometrics System Market Through 2021  ... " Global Biometrics Market By Type, By End ... - 2021", the global biometrics market is projected to ... growing security concerns across various end use sectors such ...
Breaking Biology News(10 mins):